非小细胞肺癌免疫检查点抑制剂假性进展的研究进展
Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
童亚军 1龙咏 2张帆 2李军烽2
作者信息
- 1. 414000 岳阳,岳阳市中心医院肿瘤科
- 2. 415000 常德,湘雅常德医院肿瘤科
- 折叠
摘要
免疫检查点抑制剂的出现极大地改善了晚期肺癌患者的预后,但其可能会导致假性进展,使临床评估和管理变得复杂化.假性进展表现为肿瘤暂时性增大或出现新病变等,继续治疗后影像学上出现改善,多不伴有临床症状恶化.目前假性进展在早期诊断方面仍存在困难,其发生机制尚不明确,缺乏良好的预测因素和相关生物标志物.本文通过对非小细胞肺癌免疫检查点抑制剂假性进展的研究现状进行综述,以期为使用该类药物治疗患者的临床医生提供有益的参考.
Abstract
The advent of immune checkpoint inhibitors(ICIs)has greatly improved the prognosis of advanced lung cancer patients,but can lead to pseudoprogression(PsP),which complicates clinical evaluation and management.PsP is manifested as temporary enlargement of the tumour or the appearance of new lesions,etc.,and improvement in imaging occurs with continued treatment,mostly without worsening of clinical symptoms.Currently,there are still difficulties in the early diag-nosis of PsP,and its occurrence mechanism is not yet clear,lacking good predictive factors and related biomarkers.This article reviews the current research status of PsP of ICIs in non-small cell lung cancer in order to provide helpful clinical strategies for oncologists using these drugs.
关键词
肺肿瘤/免疫检查点抑制剂/假性进展/免疫治疗Key words
Lung neoplasms/Immune checkpoint inhibitors/Pseudoprogression/Immunotherapy引用本文复制引用
基金项目
吴阶平医学基金会项目(2020)(320.6750.2020-10-34)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据